Rainer Blair Sells 47,175 Shares of Danaher Co. (NYSE:DHR) Stock

Danaher Co. (NYSE:DHR) CEO Rainer Blair sold 47,175 shares of the stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the completion of the sale, the chief executive officer now owns 115,995 shares in the company, valued at approximately $28,908,273.90. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Danaher Stock Up 0.3 %

Shares of NYSE DHR opened at $246.45 on Friday. The company has a 50 day simple moving average of $248.87 and a 200 day simple moving average of $231.08. The firm has a market cap of $182.54 billion, a PE ratio of 41.77, a price-to-earnings-growth ratio of 4.19 and a beta of 0.83. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $259.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.37.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The firm’s quarterly revenue was down 2.6% on a year-over-year basis. During the same quarter last year, the business earned $2.36 EPS. On average, research analysts forecast that Danaher Co. will post 7.64 EPS for the current year.

Danaher Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, April 26th. Investors of record on Thursday, March 28th were issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date of this dividend was Wednesday, March 27th. This is a positive change from Danaher’s previous quarterly dividend of $0.24. Danaher’s dividend payout ratio (DPR) is 18.31%.

Wall Street Analyst Weigh In

DHR has been the subject of a number of research reports. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Raymond James lifted their target price on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. KeyCorp lifted their target price on shares of Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Robert W. Baird lifted their target price on shares of Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a report on Wednesday. Finally, Barclays lifted their target price on shares of Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a report on Wednesday. Six analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and a consensus target price of $270.00.

Institutional Trading of Danaher

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tsfg LLC increased its position in Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares during the period. Cape Investment Advisory Inc. acquired a new stake in Danaher during the 4th quarter valued at approximately $25,000. BKM Wealth Management LLC acquired a new stake in Danaher during the 4th quarter valued at approximately $27,000. Redmont Wealth Advisors LLC acquired a new stake in Danaher during the 1st quarter valued at approximately $30,000. Finally, Wetzel Investment Advisors Inc. acquired a new stake in Danaher during the 4th quarter valued at approximately $29,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.